{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T17:27:05Z","timestamp":1786728425313,"version":"build-2736575974"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:p>Anti-vascular endothelial growth factor (anti-VEGF) therapy has transformed the management of retinal vascular diseases over the past two decades. Beginning with the foundational identification of VEGF as the principal driver of ocular neovascularization, the field has evolved from early agents such as pegaptanib and bevacizumab to more potent molecules including ranibizumab, aflibercept, brolucizumab, and faricimab. In India, the landscape is shaped by unique economic and epidemiological factors, including a high burden of diabetic retinopathy and age-related macular degeneration, limited healthcare reimbursement, and the significant role of biosimilar ranibizumab products in expanding access. This article provides a comprehensive overview of the historical development, pharmacology, regulatory milestones, safety considerations, and current clinical use of anti-VEGF agents in the Indian context, with emphasis on strategies to deliver equitable, high quality retinal care across a diverse population.<\/jats:p>","DOI":"10.4103\/ijo.ijo_385_26","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:01:07Z","timestamp":1777478467000},"page":"635-638","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Peep into anti-vascular endothelial growth factor"],"prefix":"10.4103","volume":"74","author":[{"given":"Lalit","family":"Verma","sequence":"first","affiliation":[{"name":"Department of Vitreo Retinal Services, Centre for Sight Eye Institute, Dwarka, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shweta","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Vitreo Retinal Services, Centre for Sight Eye Institute, Dwarka, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Obuli","family":"Ramachandran","sequence":"additional","affiliation":[{"name":"Department of Vitreo Retinal Services, Centre for Sight Eye Institute, Dwarka, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"R1-20260514","doi-asserted-by":"crossref","first-page":"437","DOI":"10.4103\/0301-4738.36478","article-title":"A comparative debate on the various anti-vascular endothelial growth factor drugs: Pegaptanib sodium (Macugen), ranibizumab (Lucentis) and bevacizumab (Avastin)","volume":"55","author":"Nagpal","year":"2007","journal-title":"Indian J Ophthalmol"},{"key":"R2-20260514","first-page":"5397","article-title":"Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: A systematic review and meta-analysis","volume":"9","author":"Ba","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"R3-20260514","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: Two-year results from a comparative effectiveness randomized clinical trial","volume":"123","author":"Wells","year":"2016","journal-title":"Ophthalmology"},{"key":"R4-20260514","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.ophtha.2010.02.022","article-title":"Ranibizumab for macular edema following central retinal vein occlusion: Six-month primary end point results of a phase III study","volume":"117","author":"Brown","year":"2010","journal-title":"Ophthalmology"},{"key":"R5-20260514","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1007\/s00417-024-06387-z","article-title":"Intravitreal anti-vascular endothelial growth factor and combined photodynamic therapy for pachychoroid neovasculopathy: Long-term treatment outcomes","volume":"262","author":"Tanaka","year":"2024","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R6-20260514","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1016\/j.ophtha.2013.06.010","article-title":"Ranibizumab in myopic choroidal neovascularization: The 12-month results from the REPAIR study","volume":"120","author":"Tufail","year":"2013","journal-title":"Ophthalmology"},{"key":"R7-20260514","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2147\/PHMT.S391591","article-title":"Role of anti-vascular endothelial growth factor (Anti-VEGF) in the treatment of retinopathy of prematurity: A narrative review in the context of middle-income countries","volume":"14","author":"Dogra","year":"2023","journal-title":"Pediatric Health Med Ther"},{"key":"R8-20260514","doi-asserted-by":"crossref","first-page":"209","DOI":"10.4103\/ijo.IJO_72_21","article-title":"Current perspectives on use of anti-vascular endothelial growth factor agents for retinal disorders","volume":"69","author":"Sengupta","year":"2021","journal-title":"Indian J Ophthalmol"},{"key":"R9-20260514","first-page":"729","article-title":"Retinal neovascularization","volume":"54","author":"Wise","year":"1956","journal-title":"Trans Am Ophthalmol Soc"},{"key":"R10-20260514","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: Therapeutic implications","volume":"285","author":"Folkman","year":"1971","journal-title":"N Engl J Med"},{"key":"R11-20260514","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1387\/ijdb.103216dr","article-title":"From the discovery of vascular endothelial growth factor to the introduction of avastin in clinical trials-An interview with Napoleone Ferrara by Domenico Ribatti","volume":"55","author":"Ferrara","year":"2011","journal-title":"Int J Dev Biol"},{"key":"R12-20260514","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1167\/tvst.5.2.10","article-title":"VEGF and intraocular neovascularization: From discovery to therapy","volume":"5","author":"Ferrara","year":"2016","journal-title":"Transl Vis Sci Technol"},{"key":"R13-20260514","first-page":"574","article-title":"Vascular endothelial growth factor\/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model","volume":"145","author":"Miller","year":"1994","journal-title":"Am J Pathol"},{"key":"R14-20260514","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1200\/JCO.2001.19.3.843","article-title":"Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer","volume":"19","author":"Gordon","year":"2001","journal-title":"J Clin Oncol"},{"key":"R15-20260514","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"R16-20260514","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.ophtha.2006.02.027","article-title":"Pegaptanib sodium for neovascular age-related macular degeneration: Two-year safety results of the two prospective, multicenter, controlled clinical trials","volume":"113","author":"D\u2019Amico","year":"2006","journal-title":"Ophthalmology"},{"key":"R17-20260514","first-page":"361","article-title":"Ranibizumab: Phase III clinical trial results","volume":"19","author":"Rosenfeld","year":"2006","journal-title":"Ophthalmol Clin North Am"},{"key":"R18-20260514","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Martin","year":"2011","journal-title":"N Engl J Med"},{"key":"R19-20260514","first-page":"559","article-title":"Incidence of endophthalmitis after intravitreal injections: Risk factors, microbiology profile, and clinical outcomes","volume":"26","author":"Mishra","year":"2018","journal-title":"Ocul Immunol Inflamm"},{"key":"R20-20260514","doi-asserted-by":"crossref","first-page":"545","DOI":"10.4103\/ijo.IJO_431_17","article-title":"Using intravitreal bevacizumab (Avastin\u00ae) - Indian scenario","volume":"65","author":"Kumar","year":"2017","journal-title":"Indian J Ophthalmol"},{"key":"R21-20260514","doi-asserted-by":"crossref","first-page":"64","DOI":"10.4103\/0974-9233.171784","article-title":"Incidence of endophthalmitis after intravitreal bevacizumab using aliquots prepared on-site in 2 operating rooms in Kuwait","volume":"23","author":"Wani","year":"2016","journal-title":"Middle East Afr J Ophthalmol"},{"key":"R22-20260514","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/eye.2013.1","article-title":"Bevacizumab vs ranibizumab-An appraisal of the evidence from CATT and IVAN","volume":"27","author":"Ahfat","year":"2013","journal-title":"Eye (Lond)"},{"key":"R23-20260514","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"R24-20260514","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1097\/ICU.0000000000000424","article-title":"Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: Recent clinically relevant findings from DRCR.net Protocol T","volume":"28","author":"Cai","year":"2017","journal-title":"Curr Opin Ophthalmol"},{"key":"R25-20260514","doi-asserted-by":"crossref","first-page":"694","DOI":"10.4103\/0301-4738.99855","article-title":"Cluster endophthalmitis following multiple intravitreal bevacizumab injections from a single use vial","volume":"64","author":"Khan","year":"2016","journal-title":"Indian J Ophthalmol"},{"key":"R26-20260514","doi-asserted-by":"crossref","first-page":"596","DOI":"10.4103\/ijo.IJO_992_16","article-title":"Real-world evidence of safety profile of intravitreal bevacizumab (Avastin) in an Indian scenario","volume":"65","author":"Jain","year":"2017","journal-title":"Indian J Ophthalmol"},{"key":"R27-20260514","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.4103\/ijo.IJO_1602_19","article-title":"All India Ophthalmological Society members\u2019 survey: Practice pattern of intravitreal anti-vascular endothelial growth factor injection","volume":"68","author":"Sundar","year":"2020","journal-title":"Indian J Ophthalmol"},{"key":"R28-20260514","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: Phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"key":"R29-20260514","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.2147\/OPTH.S328160","article-title":"Brolucizumab in neovascular age-related macular degeneration - Indian real-world experience: The BRAILLE study","volume":"15","author":"Chakraborty","year":"2021","journal-title":"Clin Ophthalmol"},{"key":"R30-20260514","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.oret.2021.05.003","article-title":"Clinical characteristics and outcomes of eyes with intraocular inflammation after brolucizumab: Post hoc analysis of HAWK and HARRIER","volume":"6","author":"Singer","year":"2022","journal-title":"Ophthalmol Retina"},{"key":"R31-20260514","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): Two randomised, double-masked, phase 3, non-inferiority trials","volume":"399","author":"Heier","year":"2022","journal-title":"Lancet"},{"key":"R32-20260514","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","article-title":"Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial","volume":"403","author":"Lanzetta","year":"2024","journal-title":"Lancet"},{"key":"R33-20260514","doi-asserted-by":"crossref","first-page":"141","DOI":"10.4103\/tjo.tjo_62_17","article-title":"Dexamethasone implant (0.7 mg) in Indian patients with macular edema: Real-life scenario","volume":"8","author":"Nagpal","year":"2018","journal-title":"Taiwan J Ophthalmol"},{"key":"R34-20260514","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.4103\/IJO.IJO_2973_23","article-title":"Brolucizumab-associated intraocular inflammation in Indian patients by VRSI study group","volume":"72","author":"Agarwal","year":"2024","journal-title":"Indian J Ophthalmol"},{"key":"R35-20260514","first-page":"368","article-title":"Real life clinical effectiveness of Razumab\u00ae (world\u2019s first biosimilar ranibizumab) in wet age-related macular degeneration: A subgroup analysis of pooled retrospective RE-ENACT study","volume":"6","author":"Sharma","year":"2018","journal-title":"Int J Ophthalmol Eye"},{"key":"R36-20260514","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000488602","article-title":"Real-life clinical effectiveness of Razumab\u00ae (the world\u2019s first biosimilar of ranibizumab) in retinal vein occlusion: A subgroup analysis of the pooled retrospective RE-ENACT study","volume":"241","author":"Sharma","year":"2019","journal-title":"Ophthalmologica"},{"key":"R37-20260514","doi-asserted-by":"crossref","first-page":"347","DOI":"10.4103\/ijo.IJO_2516_20","article-title":"Clinical efficacy and safety of Razumab\u00ae (CESAR) study: Our experience with the world\u2019s first biosimilar ranibizumab","volume":"69","author":"Verma","year":"2021","journal-title":"Indian J Ophthalmol"},{"key":"R38-20260514","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1038\/s41433-024-03001-8","article-title":"Biosimilar ranibizumab in India- overview of phase 3 clinical trial designs","volume":"38","author":"Sharma","year":"2024","journal-title":"Eye (Lond)"},{"key":"R39-20260514","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.4103\/ijo.IJO_2118_21","article-title":"A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin\u2019s ranibizumab with Lucentis\u00ae in patients with neovascular age-related macular degeneration","volume":"70","author":"Singh","year":"2022","journal-title":"Indian J Ophthalmol"},{"key":"R41-20260514","doi-asserted-by":"crossref","first-page":"e1764","DOI":"10.1016\/S2214-109X(22)00411-9","article-title":"Prevalence of diabetic retinopathy in India stratified by known and undiagnosed diabetes, urban-rural locations, and socioeconomic indices: Results from the SMART India population-based cross-sectional screening study","volume":"10","author":"Raman","year":"2022","journal-title":"Lancet Glob Health"},{"key":"R42-20260514","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.4103\/IJO.IJO_199_23","article-title":"Prevalence of age-related macular degeneration and associated factors in Indian cohort in a tertiary care setting","volume":"71","author":"Hamati","year":"2023","journal-title":"Indian J Ophthalmol"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_385_26","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T16:26:46Z","timestamp":1786724806000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_385_26"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_385_26","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"assertion":[{"value":"2026-02-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}